Episode 191 - July 31, 2026

What It Covers

Biotech Hangout Episode 191 covers Q2 2026 biotech sector performance with XBI up 24% year-to-date, reverse merger trends, AI's role in drug discovery, major BD deals including J&J's $785M Sail Biomedicines partnership and argenx's $2.2B Forte acquisition, FDA advisory committee outcomes, and Alnylam's guidance cut on Amvutra.

Key Questions Answered

• •Biotech Sector Positioning: XBI is up 24% year-to-date versus S&P 500 at 9% and Nasdaq at 8%, with three structural tailwinds supporting continued outperformance: FDA leadership turnover shifting from headwind to tailwind, 14 US biotech IPOs already surpassing all of 2025's eight, and over $300B in pharma revenue at risk from patent expirations driving sustained M&A demand through the next decade.
• •Reverse Merger Mechanics: Approximately 10 companies went public via reverse merger in 2026, matching or exceeding traditional IPO volume. Investors favor this route because it allows confidential due diligence unavailable in standard IPOs, closes faster amid political uncertainty around midterms, and post-market performance has been strong with deals consistently oversubscribed. Syndicate quality now rivals traditional IPOs, eliminating the prior perception disadvantage.
• •AI in Drug Discovery — Agentic Tools Over Molecule Generation: The real productivity gain from AI in biotech is not computational molecule design but agentic tools like Anthropic's Claude that amplify individual scientists. Tasks previously requiring weeks — writing protocols, designing experiments, analyzing results, drafting papers — now take minutes. Platforms like Cadence added over 150,000 scientists in months, signaling that AI-as-lab-assistant is the near-term transformational application.
• •In Vivo CAR-T Deal Landscape: J&J's $785M upfront partnership with Sail Biomedicines, with an option to acquire for an additional $2.6B, marks J&J's second in vivo CAR-T deal after its Colonia collaboration. Combined with Eli Lilly's $2.4B Orna deal and $7B Colonia deal, the in vivo CAR-T space is consolidating rapidly. Investors should monitor Legend Biotech, which faces CEO departure, Gilead's Anito Cell approval expected in December, and J&J's reduced acquisition incentive.
• •FDA Advisory Committees Signal Balanced Standards: Two high-profile AdComs returned this week: Capricor's Dermiocell for DMD was voted down 3-9, while Replimmune's RP1 for melanoma was approved 10-3. Both outcomes demonstrate that post-Marty Makary FDA leadership is not broadly loosening approval standards. Investors treating leadership turnover as a blanket green light should recalibrate; the agency continues applying rigorous statistical scrutiny, particularly around protocol changes and endpoint measurement methodology.
• •Alnylam Amvutra Guidance Cut — Stabilizer vs. Silencer Dynamics: Alnylam cut Amvutra guidance for the second time in three quarters, sending shares down roughly 30%. The core commercial risk is that community cardiologists may default to cheaper oral stabilizers like Tafamidis when efficacy appears comparable. The Ionis AZ outcomes trial failure on combo benefit reinforces this concern. Alnylam's next-gen silencer outcomes trial, structured as a Tafamidis combo study, now carries elevated risk pending ESC data presentation.